Bioequivalence and Bioavailability Forum 23:36 CET

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

Achievwin
Junior

US,
2017-10-26 16:12

Posting: # 17923
Views: 1,926
 

 Allowed Time gap between Cohorts in a BE study [Design Issues]

Folks:

Are there any limitations on the maximum days allowed between different cohorts (let us say Cohort 1 and Cohort 2) in a Cross over BE study? Needless to say the Bioanalysis and PK work will be carried out after completion of all cohorts.

Thanks a lot for your input

Achieve and Win
Helmut
Hero
avatar
Homepage
Vienna, Austria,
2017-10-26 19:08

@ Achievwin
Posting: # 17928
Views: 1,654
 

 Allowed Time gap between Cohorts in a BE study

Hi Achievwin,

» Are there any limitations on the maximum days allowed between different cohorts (let us say Cohort 1 and Cohort 2) in a Cross over BE study?

Maybe this presentation gives you some ideas. The FDA uses the elastic clause “months apart” to describe a large interval.

» Needless to say the Bioanalysis and PK work will be carried out after completion of all cohorts.

Take care that you don’t run into issues with the validated long-term stability. :-D

Cheers,
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. ☼
Science Quotes
ElMaestro
Hero

Denmark,
2017-10-26 23:01

@ Achievwin
Posting: # 17929
Views: 1,564
 

 Allowed Time gap between Cohorts in a BE study

Hi Achievwin,

» Are there any limitations on the maximum days allowed between different cohorts (let us say Cohort 1 and Cohort 2) in a Cross over BE study? Needless to say the Bioanalysis and PK work will be carried out after completion of all cohorts.

I agree with Helmut. There is no real limit in my experience.
From a stats point of view it isn't an issue at all. Of course there are a few situations when you wish to avoid seasonal variations between cohorts (rhinitis or asthma patients etc), but you probably have volunteers?

Re. your sentence "Needless to say the Bioanalysis and PK work will be carried out after completion of all cohorts.": I think it is better in practice to analyse samples after each cohort and accumulate the PK-data until the time of stats analysis.

if (3) 4

Best regards,
ElMaestro

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.
Activity
 Thread view
Bioequivalence and Bioavailability Forum |  Admin contact
18,923 posts in 4,039 threads, 1,284 registered users;
online 14 (1 registered, 13 guests [including 7 identified bots]).

Whenever you find that you are on the side of the majority,
it is time to pause & reflect.    Mark Twain

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
HTML5 RSS Feed